Clinical, endocrine and neurochemical effects of moclobemide in depressed patients

  title={Clinical, endocrine and neurochemical effects of moclobemide in depressed patients},
  author={Basil Alevizos and John Hatzimanolis and Manolis Markianos and C. Stefanis},
  journal={Acta Psychiatrica Scandinavica},
The clinical efficacy of the monoamine oxidase A inhibitor moclobemide and its effect on the dexamethasone suppression test (DST) and plasma and urine methoxyhydroxyphenylglycol (MHPG) were investigated in 26 depressed patients during a 4‐week clinical trial. Fourteen patients (54%) responded favourably to the treatment (50% or more reduction of the Hamilton Rating Scale for Depression score). All (8) patients with an abnormal DST responded to treatment; 11 of 16 patients with a normal DST did… Expand
The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline
The dexamethasone suppression test (DST) may be a useful adjunct for predicting and evaluating the outcome of antidepressant therapy. Expand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Comparative Tolerability Profiles of the Newer versus Older Antidepressants
The availability of new-generation antidepressants increases the likelihood of clinical response with a reduction in unwanted toxicity, and Monoamine oxidase (MAO) inhibitors have also been refined; reversible inhibitors of MAO-type A afford protection against the usually feared hypertensive reaction to indirect sympathomimetic substances. Expand
S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms
In patients with T2DM there is no correlation between S100B serum levels and newly detected mild depressive symptoms, and the brain biochemistry pathways of depression in T2 DM warrant further investigation in a larger scale population. Expand
An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review
With increased understanding of the neurobiology of depression, the role of the noradrenergic system is achieving greater significance. Unfortunately, the exact role of noradrenaline in depressiveExpand
Atypical depression spectrum disorder – neurobiology and treatment
  • H. Murck
  • Medicine, Psychology
  • Acta Neuropsychiatrica
  • 2003
Hypericum extracts might be an alternative pharmacological intervention, which demonstrated therapeutic efficacy in the symptom range of the spectrum, and a decrease in hypothalamus–pituitary–adrenocortical (HPA) axis activity seems to exist. Expand
Hypothalamic-pituitary-adrenocortical axis: neuropsychiatric aspects.
  • L. Jacobson
  • Psychology, Medicine
  • Comprehensive Physiology
  • 2014
Greater attention to patient heterogeneity and more consistent approaches to assessing treatment effects on HPA function may solidify the value of HPA measures in predicting treatment response or developing novel strategies to manage psychiatric disease. Expand


Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
A significant correlation was found between MHPG pretreatment values and treatment outcome, and a significant correlationwas found betweenMHPG pret treatment values and Treatment outcome. Expand
Moclobemide and clomipramine in the treatment of depression
Because of its low toxicity, good tolerance, its selectivity and reversibility moclobemide may be a better alternative than the older monoamine oxidase inhibitors. Expand
Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
moclobemide seemed to be more effective in retarded depressives, maprotiline was superior in alleviating depressive agitation and sleep disturbances, and compared to tricyclic antidepressants a high CSF/plasma ratio could be detected. Expand
Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline.
There was no overlap in individual values between the responders and nonresponders to either drug, and treatment with eigher imipramine or amitriptyline was associated with a significant decrease in MHPG excretion, which was independent of clinical response. Expand
Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility.
• Pilot studies suggest that changes in response to the dexamethasone suppression test (DST) in melancholic patients receiving antidepressants might represent a laboratory marker of clinicalExpand
MHPG as a predictor of antidepressant response to imipramine and maprotiline.
To explore the hypothesis that depressed patients with low pretreatment levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) respond more favorably to antidepressant drugs which act onExpand
A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.
A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder, and proved to be a well-tolerated and effective antidepressant. Expand
Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment.
It has been found that both low pre-treatment urinary MHPG and low CSF 5-HIAA values are associated with a response to imipramine and there was not a bimodal distribution for CSF 3-methoxy-4-hydrophenethyleneglycol. Expand
Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
The results suggest that Ro 11-1163 is an effective antidepressant that has to be further evaluated by double-blind clinical trials. Expand
Phenelzine in depressed patients. Effects on urinary MHPG excretion in relation to clinical response.
Depressed patients' treatment with the monoamine oxidase inhibiting antidepressant, phenelzine, developed marked reductions in urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) excretion. PretreatmentExpand